12 unknown. 12 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Unknown 12 |
| Phase 1 | 3 | Unknown 3 |
| Phase 3 | 2 | Unknown 2 |
Follow Cystic Fibrosis: new trials by email Literature Review of Cystic Fibrosis trials Research Report on Cystic Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection Posaconazole 100 MG [Noxafil], Posaconazole 40 MG/ML - Cystic Fibrosis, Aspergillosis | Phase 2 / Phase 3 | Unknown | Bambino Gesù Hospital and Research Institute | 135 | 2021-04-22 | 2021-07-19 |
| Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis S-1226 - Cystic Fibrosis, Bronchiectasis | Phase 2 | Unknown | SolAeroMed Inc. | 12 | 2019-08-08 | 2021-06-16 |
| DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis Tobramycin - Cystic Fibrosis | Phase 1 / Phase 2 | Unknown | University Medical Center Groningen | 10 | 2019-05-29 | 2021-10-01 |
| SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects Inhaled AR-501, Inhaled Placebo - Cystic Fibrosis | Phase 1 / Phase 2 | Unknown | Aridis Pharmaceuticals, Inc. | 102 | 2018-12-07 | 2023-03-09 |
| Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme® AIR DNase™ - Cystic Fibrosis | Phase 2 | Unknown | Protalix | 15 | 2016-05-01 | 2016-09-28 |
| Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor Cavosonstat, Placebo - Cystic Fibrosis | Phase 2 | Unknown | Nivalis Therapeutics, Inc. | 19 | 2016-04-01 | 2016-11-21 |
| Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis Tobramycin - Cystic Fibrosis | Phase 1 / Phase 2 | Unknown | Erempharma | 36 | 2011-04-01 | 2011-04-18 |
| CFfone: A Cell Phone Support Program for Adolescents With Cystic Fibrosis CFFONE, CF website - Cystic Fibrosis | Phase 2 | Unknown | Dawkins Productions, Inc. | 146 | 2010-09-01 | 2010-08-17 |
| Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo Amitriptyline, Mannite - Cystic Fibrosis, Pneumonia | Phase 2 | Unknown | University Children's Hospital Tuebingen | 30 | 2009-05-01 | 2011-03-07 |
| Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex Azithromycin, Placebo - Cystic Fibrosis | Phase 2 | Unknown | Unity Health Toronto | 45 | 2006-02-01 | 2009-07-31 |
| Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis Normal saline IV, salt tablets - Cystic Fibrosis | Phase 2 / Phase 3 | Unknown | Bayside Health | 40 | 2004-02-01 | 2005-09-14 |
| Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease ursodiol - Cystic Fibrosis, Gastrointestinal Diseases | Phase 2 | Unknown | National Center for Research Resources (NCRR) | 20 | 1995-11-01 | 2005-06-24 |
Genetic Diseases, Inborn (2) · Respiratory Tract Diseases (2) · Aspergillosis (1) · Asthma (1) · Bronchiectasis (1) · Cholestasis (1) · Digestive System Diseases (1) · Disease (1) · Gastrointestinal Diseases (1) · Hypercapnia (1) · Lung Diseases (1) · Pancreatic Diseases (1) · Pneumonia (1) · Pseudomonas Infections (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Infant, Newborn, Diseases (12) · Digestive System Diseases (11) · Lung Diseases (11) · Pancreatic Diseases (11) · Genetic Diseases, Inborn (10) · Respiratory Tract Diseases (10) · Pathological Conditions, Signs and Symptoms (4) · Infections (3) · Pathologic Processes (3) · Bacterial Infections and Mycoses (2) · Disease Attributes (2) · Bacterial Infections (1) · Bile Duct Diseases (1) · Biliary Tract Diseases (1)
Tobramycin (2) · Amitriptyline (1) · Azithromycin (1) · Mannitol (1) · Salts (1) · Suspensions (1) · Ursodeoxycholic Acid (1) · cavosonstat (1) · perfluorooctylbromide and CO2 drug combination (1) · posaconazole (1)
Aridis Pharmaceuticals, Inc. (1) · Bambino Gesù Hospital and Research Institute (1) · Bayside Health (1) · Dawkins Productions, Inc. (1) · Erempharma (1) · National Center for Research Resources (NCRR) (1) · Nivalis Therapeutics, Inc. (1) · Protalix (1) · SolAeroMed Inc. (1) · Unity Health Toronto (1) · University Children's Hospital Tuebingen (1) · University Medical Center Groningen (1)
United States (3) · Canada (2) · France (2) · Germany (2) · Netherlands (2) · Australia (1) · Czechia (1) · Greece (1) · Ireland (1) · Israel (1) · Italy (1) · Portugal (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Adilia Warris, Prof (1) · Alan H Cohen, MD (1) · Einat Dekel, DVM (1) · Elizabeth Tullis, MD (1) · Gabriel Bellon (1) · Gerard Koppelman, Prof. (1) · Hasan S Jafri, MD, FAAP (1) · Isabelle Durieu, Pr (1) · James Chmiel, MD (1) · Joachim Riethmueller, Dr (1) · Mark Montgomery, MD (1) · Matthew T Naughton, MBBS, MD (1) · William Balistreri (1)
2008 (1), 2019 (1)